Fernando Perez-Ruiz

Summary

Country: Spain

Publications

  1. ncbi request reprint Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout
    Fernando Perez-Ruiz
    Hospital de Cruces, Pais Vasco, Spain
    Arthritis Rheum 47:356-60. 2002
  2. ncbi request reprint Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study
    Fernando Perez-Ruiz
    Seccion de Reumatologia, Hospital de Cruces, Pais Vasco, Spain
    Arthritis Rheum 55:786-90. 2006
  3. ncbi request reprint Ultrasonographic measurement of tophi as an outcome measure for chronic gout
    Fernando Perez-Ruiz
    Seccion de Reumatologia and Servicio de Radiologia, Hospital de Cruces, Baracaldo, Spain
    J Rheumatol 34:1888-93. 2007
  4. ncbi request reprint Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts
    F Perez-Ruiz
    Rheumatology Section, Hospital de Cruces, Barakaldo, Spain
    Nephron 86:287-91. 2000
  5. ncbi request reprint Imaging modalities and monitoring measures of gout
    Fernando Perez-Ruiz
    Department of Rheumatology, Hospital de Cruces, Vizcaya, Spain
    Curr Opin Rheumatol 19:128-33. 2007
  6. ncbi request reprint Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity
    Fernando Perez-Ruiz
    Rheumatology Section, Hospital de Cruces, Vizcaya, Spain
    J Clin Rheumatol 11:129-33. 2005
  7. ncbi request reprint Long-term efficacy of hyperuricaemia treatment in renal transplant patients
    Fernando Perez-Ruiz
    Hospital de Cruces, Rheumatology Section and Nephrology Division, Baracaldo, Pais Vasco, Spain
    Nephrol Dial Transplant 18:603-6. 2003
  8. ncbi request reprint Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output
    F Perez-Ruiz
    Hospital de Cruces, Baracaldo, Vizcaya, Spain
    Arthritis Rheum 47:610-3. 2002
  9. doi request reprint Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout
    Fernando Perez-Ruiz
    Hospital de Cruces, Vizcaya, Spain
    Arthritis Care Res (Hoboken) 62:1299-305. 2010
  10. doi request reprint Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Vizcaya, Spain
    Ann Rheum Dis 73:177-82. 2014

Detail Information

Publications21

  1. ncbi request reprint Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout
    Fernando Perez-Ruiz
    Hospital de Cruces, Pais Vasco, Spain
    Arthritis Rheum 47:356-60. 2002
    ..This observational, prospective study evaluates the relationship between serum urate levels during therapy and the velocity of reduction of tophi in patients with chronic tophaceous gout...
  2. ncbi request reprint Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study
    Fernando Perez-Ruiz
    Seccion de Reumatologia, Hospital de Cruces, Pais Vasco, Spain
    Arthritis Rheum 55:786-90. 2006
    ..Our objective was to ascertain the outcome of ULT withdrawal after long-term, documented control of serum urate levels...
  3. ncbi request reprint Ultrasonographic measurement of tophi as an outcome measure for chronic gout
    Fernando Perez-Ruiz
    Seccion de Reumatologia and Servicio de Radiologia, Hospital de Cruces, Baracaldo, Spain
    J Rheumatol 34:1888-93. 2007
    ..To validate the usefulness of measuring tophi with ultrasonography (US) as an outcome measure for chronic tophaceous gout...
  4. ncbi request reprint Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts
    F Perez-Ruiz
    Rheumatology Section, Hospital de Cruces, Barakaldo, Spain
    Nephron 86:287-91. 2000
    ..To evaluate the effect of nonsteroidal anti-inflammatory drug (NSAID) withdrawal on renal function in patients with chronic gout after proper control of hyperuricemia and gouty symptoms...
  5. ncbi request reprint Imaging modalities and monitoring measures of gout
    Fernando Perez-Ruiz
    Department of Rheumatology, Hospital de Cruces, Vizcaya, Spain
    Curr Opin Rheumatol 19:128-33. 2007
    ..Ultrasonography, computed tomography and magnetic resonance imaging are emerging techniques that could be used for diagnosis, evaluation, and monitoring acute and chronic gout...
  6. ncbi request reprint Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity
    Fernando Perez-Ruiz
    Rheumatology Section, Hospital de Cruces, Vizcaya, Spain
    J Clin Rheumatol 11:129-33. 2005
    ..Dosing of allopurinol should be corrected depending on renal function, but corrections based on either plasma creatinine (Pcr) or creatinine clearance (CrCl) have been suggested to be minimal standards of care...
  7. ncbi request reprint Long-term efficacy of hyperuricaemia treatment in renal transplant patients
    Fernando Perez-Ruiz
    Hospital de Cruces, Rheumatology Section and Nephrology Division, Baracaldo, Pais Vasco, Spain
    Nephrol Dial Transplant 18:603-6. 2003
    ..We therefore examine the effects of allopurinol and benziodarone therapy in a cohort of renal transplant patients...
  8. ncbi request reprint Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output
    F Perez-Ruiz
    Hospital de Cruces, Baracaldo, Vizcaya, Spain
    Arthritis Rheum 47:610-3. 2002
    ..To compare renal handling of uric acid in patients with primary gout with that of a control group...
  9. doi request reprint Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout
    Fernando Perez-Ruiz
    Hospital de Cruces, Vizcaya, Spain
    Arthritis Care Res (Hoboken) 62:1299-305. 2010
    ..To find factors associated with the development of renal colic during uricosuric therapy...
  10. doi request reprint Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Vizcaya, Spain
    Ann Rheum Dis 73:177-82. 2014
    ....
  11. doi request reprint A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis
    Fernando Perez-Ruiz
    Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Vizcaya, Spain
    Arthritis Rheum 63:4002-6. 2011
    ..This study was undertaken to reevaluate whether this stringent therapeutic target to dissolve crystals must be maintained lifelong to prevent new crystal formation...
  12. doi request reprint Evaluation and treatment of gout as a chronic disease
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital Universitario Cruces, Pza Cruces, Baracaldo, Vizcaya, Spain
    Adv Ther 29:935-46. 2012
    ..This review intends to increase the awareness of gout as a chronic deposition disease, and show that efforts should be made to properly control serum urate levels in order to achieve complete disappearance of urate crystal deposition...
  13. doi request reprint An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study
    Fernando Perez-Ruiz
    Rheumatology Department, Hospital de Cruces, Baracaldo, Spain
    J Clin Rheumatol 17:349-55. 2011
    ....
  14. doi request reprint Treating to target: a strategy to cure gout
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital de Cruces, 48600 Baracaldo, Vizcaya, Spain
    Rheumatology (Oxford) 48:ii9-ii14. 2009
    ..In the long term, reduction in the sUA below the target level will result in gout being effectively cured...
  15. pmc Imaging of gout: findings and utility
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital de Cruces, Baracaldo, Vizcaya, Spain
    Arthritis Res Ther 11:232. 2009
    ....
  16. ncbi request reprint Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?
    Fernando Perez-Ruiz
    Hospital de Cruces, Baracaldo, Pais Vasco, Spain
    Arthritis Rheum 57:1324-8. 2007
  17. ncbi request reprint Canakinumab for gout: a specific, patient-profiled indication
    Fernando Perez-Ruiz
    Rheumatology Division, Hospital Universitario Cruces, Vizcaya, Spain
    Expert Rev Clin Immunol 10:339-47. 2014
    ..Notwithstanding, the use of IL-1 blockade to prevent EAIs in gout looks promising, but no drug has yet obtained approval for such an indication. ..
  18. ncbi request reprint New treatments for gout
    Fernando Perez-Ruiz
    Joint Bone Spine 74:313-5. 2007
  19. ncbi request reprint PEG-uricase in the management of treatment-resistant gout and hyperuricemia
    MERRY R SHERMAN
    Mountain View Pharmaceuticals, Inc, 3475 S Edison Way, Menlo Park, CA 94025, USA
    Adv Drug Deliv Rev 60:59-68. 2008
    ..Two ongoing Phase 3 clinical trials include systematic assessments of gout symptoms, tophus resolution and quality of life, in addition to the primary endpoint of reduced plasma urate concentration...
  20. ncbi request reprint Outcome evaluations in gout
    H Ralph Schumacher
    Division of Rheumatology, University of Pennsylvania School of Medicine, and Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, USA
    J Rheumatol 34:1381-5. 2007
    ..Final validation of these outcomes has not yet been achieved. In summary, the unique problems of evaluating outcomes in gout are finally being addressed. While no measures are available for use yet, an agenda has been developed...
  21. ncbi request reprint Outcome measures for acute and chronic gout
    H Ralph Schumacher
    University of Florida, Gainesville, Florida, USA
    J Rheumatol 32:2452-5. 2005
    ..Five domains for acute gout outcomes and 9 for chronic gout were identified along with proposed instruments for testing and validation. The unique problems of gout evaluation can and will be addressed...